| 초록 |
Over the past decade, widespread progress in nanotechnology has produced an impressive array of nanodevices with powerful electromagnetic and therapeutic properties. Nonetheless, our capacity to precisely home these materials to regions of disease in vivo has remained very limited and, despite three decades of research, ligand-targeted nanomedicines have yet to provide a benefit to patients. A fundamental limitation of current approaches to nanoparticle targeting is that they lack mechanisms of communication and amplification through which specific targeting events could assist the targeting of materials still in circulation. This presentation will discuss our recent approaches to engineering nanomedicine via biological systems. First, we have developed drug delivery nanosystems where two distinct nanomaterials work in concert within the bloodstream to amplify tumor targeting and improve therapy in vivo, which was inspired by examples of communication in natural targeting systems (e.g. inflammatory cell recruitment to infection). Secondly, we have developed drug delivery nanosystems where tumor-derived membrane vesicles, which is an innate biological transport system, were engineered in situ to improve tumor penetration of therapeutic compounds and their therapeutic efficacy. |
